Your browser doesn't support javascript.
loading
Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.
McDonnell, Mark E; Vera, Matthew D; Blass, Benjamin E; Pelletier, Jeffrey C; King, Richard C; Fernandez-Metzler, Carmen; Smith, Garry R; Wrobel, Jay; Chen, Suzie; Wall, Brian A; Reitz, Allen B.
Afiliação
  • McDonnell ME; Fox Chase Chemical Diversity Center, Inc., 3805 Old Easton Road, Doylestown, PA 18902, USA.
Bioorg Med Chem ; 20(18): 5642-8, 2012 Sep 15.
Article em En | MEDLINE | ID: mdl-22892214
ABSTRACT
Riluzole (1) is an approved therapeutic for the treatment of ALS and has also demonstrated anti-melanoma activity in metabotropic glutamate GRM1 positive cell lines, a mouse xenograft assay and human clinical trials. Highly variable drug exposure following oral administration among patients, likely due to variable first pass effects from heterogeneous CYP1A2 expression, hinders its clinical use. In an effort to mitigate effects of this clearance pathway and uniformly administer riluzole at efficacious exposure levels, several classes of prodrugs of riluzole were designed, synthesized, and evaluated in multiple in vitro stability assays to predict in vivo drug levels. The optimal prodrug would possess the following profile stability while transiting the digestive system, stability towards first pass metabolism, and metabolic lability in the plasma releasing riluzole. (S)-O-Benzyl serine derivative 9 was identified as the most promising therapeutically acceptable prodrug.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Desenho de Fármacos / Riluzol / Esclerose Lateral Amiotrófica / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Desenho de Fármacos / Riluzol / Esclerose Lateral Amiotrófica / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article